3-Methyladenine (3-MA)

目录号:S2767 别名: NSC 66389

3-Methyladenine (3-MA) Chemical Structure

Molecular Weight(MW): 149.15

3-Methyladenine (3-MA)是一种选择性PI3K抑制剂,作用于Vps34PI3Kγ,在 HeLa细胞中IC50分别为25 μM和60 μM;永久性抑制I型PI3K,但对III型PI3K的抑制是短暂的,也会阻断自噬体的形成。

规格 价格 库存 购买数量  
RMB 579.66 现货
RMB 3010.37 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用该产品的4个实验数据:

  • MDC-labeled vacuoles were induced by AZD2014 and inhibited by autophagy inhibitor (3-MA). SMMC-7721 cells were treated with AZD2014 or rapamycin at concentrations of 100 and 600 nM, respectively, for 48 hours in the presence or absence of 3-MA, and then stained with MDC. Cells were immediately observed under a confocal microscope. Cells in the control group were treated with DMSO. bars, 20 μm.

    Am J Cancer Res, 2015, 5(1): 125-139. 3-Methyladenine (3-MA) purchased from Selleck.

    Cells were treated with DMSO, TDCIPP (100 μM) only, or pretreated with 3-MA before treatment with TDCIPP (100 μM). LC3 conversion and beclin-1 and p62 expression were assessed by western blotting at 24 h

    Food Chem Toxicol, 2017, 100:183-196. 3-Methyladenine (3-MA) purchased from Selleck.

  • PC-9/ER cells were treated with CX-4945 (5 mM) for 48 h in the presence or absence of 3-MA (2 mM) and Atg7 siRNA (100 nM). Cleavage of PARP-1 and caspase-3 was shown by Western blot analysis. CT: without CX-4945; CX: CX-4945; CX+G: CX-4945 + gefitinib; CX+E: CX-4945 + erlotinib.

    PLoS One, 2014, 9(12): e114000 . 3-Methyladenine (3-MA) purchased from Selleck.

    A: The survival ratio of AML12 cells was measured after treatment with rapamycin or 3-MA; B: Western blot was used to detect the expression of LC3 and P62 in AML12 cells treated with Rapamycin or 3-MA.

    World J Gastroenterol, 2016, 22(18): 4501-4514.. 3-Methyladenine (3-MA) purchased from Selleck.

产品安全说明书

PI3K抑制剂选择性比较

生物活性

产品描述 3-Methyladenine (3-MA)是一种选择性PI3K抑制剂,作用于Vps34PI3Kγ,在 HeLa细胞中IC50分别为25 μM和60 μM;永久性抑制I型PI3K,但对III型PI3K的抑制是短暂的,也会阻断自噬体的形成。
靶点
Vps34 [1]
(HeLa cells)
PI3Kγ [1]
(HeLa cells)
25 μM 60 μM
体外研究

3-MA对Vps34轻微的偏向性可能是由于Vps34中某个特异性的疏水环形结构可以环绕在3-MA的3-甲基基团外面造成的[1] 。据报道对于正常培养和饥饿处理的癌细胞3-MA都能引起细胞死亡。3-MA还可以不通过抑制自吞噬来抑制细胞迁移和入侵,这表明3-MA 除了抑制自吞噬之外还有其它生物功能。3-MA可以造成半胱天冬酶依赖的细胞死亡,这一功能与它对自吞噬的抑制无关。用5mM 3-MA处理葡萄糖饥饿Hela细胞可降低gfp-lc3阳性细胞比例至23%。3-MA处理细胞12到48小时内 LC3-I 的水平上升而LC3-II 水平下降。LC3-I转为为 LC3-II 的过程被3-MA抑制了。 2.5 mM 或5 mM 3-MA 处理HeLa 细胞一天并不影响细胞存活率, 而 10 mM 3-MA 处理一天会造成细胞存活率下降25.0% 。 2.5, 5 或 10 mM 3-MA 处理细胞两天分别使细胞存活率下降 11.5%, 38.0% 和79.4% 。3-MA 降低细胞存活率的作用具有时间和剂量依赖特性。3-MA 明显缩短nocodazole诱导的前中期阻断时间[2]。3-MA 通过抑制自吞噬来抑制SU11274诱导的细胞死亡[3]。 在野生型MEF细胞中延长 3-MA处理时间 (最多 9 小时) 明显造成 LC3 I 到 II 转换。延长 3-MA处理时间会明显增加GFP-LC3的聚集而wortmannin不具有此功能。3-MA介导的LC3 转换和游离 GFP 释放是ATG7依赖的。 3-MA处理会导致 p62 蛋白水平明显升高。即使在Atg5−/− 的MEF细胞中3-MA 也会使p62 水平升高,就像在DOX介导的ATG5缺失的细胞中一样 。3-MA以不同方式抑制 I 型和 III型 PI3K。与野生型细胞相比,在Tsc2−/−细胞中3-MA诱导的 LC3 I 到 LC3 II 转换过程大幅下降。3-MA会破坏mTOR复合物1的拮抗自吞噬功能[4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
95D M1;Hbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mle2N41O MoLONog> MnH2SG1UVw>? MV3y[YR2[2W|IHfyc5d1cCCrbnjpZol1d3K7IHXm[oVkfCCxZjDCSG1E M4\KVVI2PzF4NU[x
A549  M{nkNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4TVZVNuVQ>? MnHDNog> MV3EUXNQ NUH4S3plemWmdXPld{Boem:5dHigbY5pcWKrdH;yfUBm\m[nY4Sgc4YhSkSPQx?= MYKyOVcyPjV4MR?=
95D MkHaRZBweHSxc3nzJGF{e2G7 M3\iWlVuVQ>? NXXjdnFxOmh? MlHxSG1UVw>? M3nKeIlvcGmkaYTzJGJFVUNvaX7keYNm\CCjcH;weI91cWNiY3XscEBl\WG2aB?= Ml7PNlU4OTZ3NkG=
A549  NWX3[5A3SXCxcITvd4l{KEG|c3H5 MUS1cW0> M{Lpc|Jp MnvYSG1UVw>? MVLpcohq[mm2czDCSG1ENWmwZIXj[YQh[XCxcITveIlkKGOnbHyg[IVifGh? MWGyOVcyPjV4MR?=
NBL-W-S  MkHSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoXnNY1O NHSyTIk3cA>? NYfnenl3\W6qYX7j[ZMhT0GQVD22NUB1d3irY3n0fS=> NYjpfYU4OjV|MkOyNlI>
NBL-W-S  MUTBdI9xfG:|aYOgRZN{[Xl? NWSzXmpxOW2P NX:2N2IyPmh? MUHpcoNz\WG|ZYOgZ4VtdCCjcH;weI9{cXNiaX7keYNm\CCkeTDHRW5VNTZz NUfYXVBIOjV|MkOyNlI>
A2780cp  NGDTZXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\hVYwydU1? NEGxUmYycA>? M1LpdYlv[3KnYYPld{BkcXOybHH0bY4ucW6mdXPl[EBk\WyuIHTlZZRp MkjnNlU{OjJ4OUS=
A549  MkDvSpVv[3Srb36gRZN{[Xl? NWCwOYpqPW2P MmPVNog> NGm0TWh{fXCycnXzd4V{KFOSQzDpcoR2[2WmIHHjZ5VufWyjdHnvckBw\iCOQ{OtTWk> NIDUVZYzPTJ6NU[yPC=>
H157 M3flcWZ2dmO2aX;uJGF{e2G7 MmH6OY1O NWrUdlFCOmh? M17ISZN2eHC{ZYPz[ZMhW1CFIHnu[JVk\WRiYXPjeY12dGG2aX;uJI9nKEyFMz3JTS=> M3O0O|I2Ojh3NkK4
MDR MlXNRZBweHSxc3nzJGF{e2G7 MVWxNI1O M2\SV|Zp M2XZT5N1emWwZ4To[Y5{KHSqZTDwc5dmeiCxZjDhcpRq[2GwY3XyJIRzfWe| NHf2XVczPTBzOUewNS=>
HT-29  NIXVSmNCeG:ydH;zbZMhSXO|YYm= MoXZNY1O MniwOFhp MmHPSG1UVw>? MWTlcohidmOnczDic5J1\XqxbXniMYlv\HWlZXSgZ4VtdCC4aXHibYxqfHlibH;zdy=> M4fKNVI1QDR{MUW4
Microglia  M{XhcGFxd3C2b4Ppd{BCe3OjeR?= M4r2bVVuVQ>? Ml;nNlRp M1TFXIRm[3KnYYPld{BpgXCxeHnhMYlv\HWlZXSgZ4VtdCCmZXH0bC=> MY[yOFgyQDZyMR?=
A2780cp NV3ncmdFSXCxcITvd4l{KEG|c3H5 MUCyMlVuVQ>? MkK4NYg> Ml3k[IRJOk9? NU\VV|RX\W6qYX7j[ZMh[2m|cHzheIlvNWmwZIXj[YQh[2WubDDk[YF1cA>? NH[xUGozPDhzN{m0Oi=>
HepG2 MoXHSpVv[3Srb36gRZN{[Xl? NW[5ZpRpPW2P MWe0bC=> MmXtbY5kemWjc3XzJGhNKHKnbHXhd4U> M{O2WlI1PzF|NUi3
A549 MX7BdI9xfG:|aYOgRZN{[Xl? MojKOY1O NX[3PGY6PDiq M372OIRm[3KnYYPld{B1cGVicHXyZ4VvfGGpZTDv[kBk\WyuIHTlZZRpKGGwZDDlfJBz\XO|aX;uJIxmfmWuczDv[kBk[XOyYYPlMVMtKEKnY3zpck0yKGGwZDDMR|MuUUl? NIfmXYgzPDdyNkOwNy=>
U2OS NXnYVXNySXCxcITvd4l{KEG|c3H5 M2LRO|ExdU1? M3LyU|I1cA>? MnTJbY51\W6|aX\p[ZMhfGinIHfyc5d1cCCrbnjpZol1cW:wIH;mJJRp\SCXMl;TJINmdGy|IHnu[JVk\WRiYomgSI95 NV7pc4E4OjR4M{mwNVM>
Saos-2 MVvBdI9xfG:|aYOgRZN{[Xl? NXzOc2pNOTCvTR?= M{S3PVI1cA>? NUHYb5lScW62ZX7zbYZq\XNidHjlJIdzd3e2aDDpcohq[mm2aX;uJI9nKHSqZTDVNm9UKGOnbHzzJIlv\HWlZXSgZpkhTG:6 NUfudnc3OjR4M{mwNVM>
A549 M4fjUWFxd3C2b4Ppd{BCe3OjeR?= M{XiUFExdU1? MofROFhp NEjGWFZi[2OnbHXyZZRmeyC2aHWgdoVlfWO2aX;uJI9nKGOnbHygeoli[mmuaYT5JIlv\HWlZXSgZpkhWFS[ NVTyNXBVOjR4Mk[3NlI>
HCT116  NEDKfHRCeG:ydH;zbZMhSXO|YYm= NGXT[402dU1? NWrSVIplOjSq MoTq[Y5p[W6lZYOgeIhmKGGyb4D0c5NqeyCrbnT1Z4VlKGK7IHHwbYdmdmmw NGHTTVEzPDZ{NkWyNi=>
HGC-27 MnXSSpVv[3Srb36gRZN{[Xl? M1zIXFExdU1? NV;jeZZbOWh? MmPIbY5pcWKrdIOgeIhmKGOnbHygeoli[mmuaYT5JIxwe3NiYomgVmFFODBzIH;yJG1MNTJ{ME[= NFLQOZIzPDRzNkO0PS=>
U2OS  NVXaXmNlTnWwY4Tpc44hSXO|YYm= M{n3TlAvPS9zbV2= MX60PIg> NGDGTXFqdmS3Y3XzJJNidGmwb335Z4lvNWmwZIXj[YQh[2WubDD2bYFjcWyrdImgcI9{ew>? NGHR[|AzPDN3OEO0Ni=>
MG-63 M4TXTGZ2dmO2aX;uJGF{e2G7 NYnMcnpTOC53L{HtUS=> M3XvS|Q5cA>? M1fWN4lv\HWlZYOgd4FtcW6xbYnjbY4ucW6mdXPl[EBk\WyuII\pZYJqdGm2eTDsc5N{ NH3C[2MzPDN3OEO0Ni=>
MG-63 MYDBdI9xfG:|aYOgRZN{[Xl? MWWwMlUwOW2P NF:1SGQ{Omh? NX\pb45Q\W6qYX7j[ZMhe2GuaX7vcZlkcW5vaX7keYNm\CClZXzsJIFxd3C2b4Ppdy=> M{noXlI1OzV6M{Sy
MG-63 MWDBdI9xfG:|aYOgRZN{[Xl? MkjoNVBuVQ>? NIPqWVgyOmh? NWK1dI9T\W6qYX7j[ZMhTFBvaX7keYNm\CCjcH;weI9{cXN? NXjYZlE2OjR|NUizNFE>
NTUB1 MmrxRZBweHSxc3nzJGF{e2G7 NXfMTlNIPW2P MWmxMlVp NEj5S3pxd3SnboTpZZRmeyClZXzlZ495cWJvaX7keYNm\CCjcH;weI9{cXN? NFO1fpYzPDN2OUG3Oi=>
T24 MX\BdI9xfG:|aYOgRZN{[Xl? MY[1cW0> MoPGNU42cA>? MoTkdI91\W62aXH0[ZMh[2WuZXPvfIljNWmwZIXj[YQh[XCxcITvd4l{ NELDcmkzPDN2OUG3Oi=>
SGC-7901  M2PQVmFxd3C2b4Ppd{BCe3OjeR?= MYqycW0> Mlm4NYg> NUDQbplWcW6lcnXhd4V{KEODLUSgbY5lfWOnZDDhdI9xfG:|aYO= NH3Uc2kzPDN{MUO0NC=>
SMMC-7721 NELkOllCeG:ydH;zbZMhSXO|YYm= NUXSfVZmOm2P NHPNeVEycA>? M1v2d4lv[3KnYYPld{BESS12IHnu[JVk\WRiYYDvdJRwe2m| NXnJXYtpOjR|MkGzOFA>
ECSCs  MoO4RZBweHSxc3nzJGF{e2G7 MYOxNI1O NYS3SHc1PGh? M3\4O4Rm[3KnYYPld{Bz[XCjbYnjbY4ufHKnYYTl[EBieG:ydH;zbZM> NIjIUlEzPDNzOUGwPS=>
MCF-7  NGDrS41HfW6ldHnvckBCe3OjeR?= NVrRS4R3OTCvTR?= NWLybIJJOjSq M1rjd4lvcGmkaYTzJJRp\SCjdYTvdIhi\3liaX7keYNm\CCkeTDjbIVud3SqZYLhdJkh\HK3Z4O= MkfTNlQ{OTV3N{i=
UOK257 M2\pbGFxd3C2b4Ppd{BCe3OjeR?= M1;6N|VuVQ>? NVf4V5Z5O2h? NXr6UJY3\W6qYX7j[ZMheGGlbHn0ZZhmdC2vZXTpZZRm\CCjcH;weI9{cXQEoB?= NIriUWgzPDNyNU[wOC=>
ACHN-5968 MWHBdI9xfG:|aYOgRZN{[Xl? NH;ENnM2dU1? NEC4S|Y{cA>? MlfG[Y5p[W6lZYOgdIFkdGm2YYjlcE1u\WSrYYTl[EBieG:ydH;zbZPDqA>? NULJb4lDOjR|MEW2NFQ>
Huh7 MnfVRZBweHSxc3nzJGF{e2G7 NHK5WWQzdU1? M3\ZRlEzcA>? NVj4SZE1TE2VTx?= MlLWbY5pcWKrdIOgRXpFQDB3NT3pcoR2[2WmIHPlcIwh\GWjdHi= NGfafG8zPDJ7N{OwNC=>
Hep3B NFv4bJhCeG:ydH;zbZMhSXO|YYm= NHXvfFczdU1? Mlf4NVJp NVnFZVVwTE2VTx?= M2r1e4lvcGmkaYTzJGFbTDhyNUWtbY5lfWOnZDDj[YxtKGSnYYTo MVeyOFI6PzNyMB?=
RKO MlLzSpVv[3Srb36gRZN{[Xl? NGXLPXIzdU1? MlfZNYg> NGHmdGhFVVOR MnzB[Y5p[W6lZYOgZ4VtdCCmZXH0bEBjgSCpZXzkZY5idXmlaX6= NF3qSG8zPDJ7MUe3Oy=>
HepG2 E47 M4iyNmZ2dmO2aX;uJGF{e2G7 NIjJenozNjWvTR?= MoS0OFhp MWjpcoNz\WG|ZYOgeIhmKHSxeHnjbZR6KG:oIFHBMEBDW09uIHHu[EBES2x2 M{LvNVI1Ojd|N{O4
LoVo  NILRTpdCeG:ydH;zbZMhSXO|YYm= NV;TdGxiPW2P MXS0PIg> MYjlcohidmOnczDER2EucW6mdXPl[EBieG:ydH;zbZMv M4jw[FI1OjBzOEGy
WiDr MVzGeY5kfGmxbjDBd5NigQ>? NILJRXEyOG2P M3mwXVFp M2LPc4lvcGmkaYTzJHBESkxvaX7keYNm\CCOQ{OgTWkh\XiycnXzd4lwdg>? MlXCNlQyQTB2OEm=
H1299  NGi0PFJHfW6ldHnvckBCe3OjeR?= M4HaVlExdU1? MlLnOIg> MXPpcoNz\WG|ZYOgZ4l{eGyjdHnuMYlv\HWlZXSgZ4VtdCCmZXH0bC=> NH;TSpAzPDF5M{KwPC=>
H460 M3vQVWZ2dmO2aX;uJGF{e2G7 MWWxNI1O M3qySlRp M2Pqcolv[3KnYYPld{BkcXOybHH0bY4ucW6mdXPl[EBk\WyuIHTlZZRp MX2yOFE4OzJyOB?=
A549 MXrGeY5kfGmxbjDBd5NigQ>? MVixNI1O NIHDTGo1cA>? M3HQfolvcGmkaYTzJIF2fG:yaHHnfUBqdmS3Y3XkJIJ6KGm{cnHkbYF1cW:w MmXYNlQyPDJ5M{W=
Hep3B NIH6U2hCeG:ydH;zbZMhSXO|YYm= MkXDOY1O MWOyOIg> MXzheJRmdnWjdHXzJHRPTi4QsTDwdo91\WO2aX;uJIFo[Wmwc4Sgd4VzfW1ic4ThdpZifGmxbj3t[YRq[XSnZDDhdI9xfG:|aYO= NYTTbZF6OjRyNk[2PVM>
SMMC-7721 NX7HW|ZXSXCxcITvd4l{KEG|c3H5 NXfrTnN4PW2P M3zrfVI1cA>? NWW4b3NS[XS2ZX71ZZRmeyCWTl[t{tEheHKxdHXjeIlwdiCjZ3HpcpN1KHOncoXtJJN1[XK4YYTpc44udWWmaXH0[YQh[XCxcITvd4l{ M13NPVI1ODZ4Nkmz
HO8910 NVXlbZNqSXCxcITvd4l{KEG|c3H5 NHfnNlkyOG2P NYTZUJU3OTKq M1jVPYVvcGGwY3XzJGIyQS2rbnT1Z4VlKGGyb4D0c5Nq Ml3LNlM6QDN4MUC=
MCF7 NFPPXnNHfW6ldHnvckBCe3OjeR?= MXO1cW0> NFPiSFYzPGh? NF\FUJZqdmO{ZXHz[ZMhS3WRIHnu[JVk\WRiY3XscEBl\WG2aB?= NGfMVmMzOzl4Mk[yPS=>
HONE-1  NEPxNmZHfW6ldHnvckBCe3OjeR?= MnPXOY1O NWTVOppzOWh? MVjy[ZBz\XO|ZYOgOpIudWWmaXH0[YQhWk:VIIDyc4R2[3Srb36= NYj1TY53OjN6OUKzOVg>
HeLa NUTZZm96TnWwY4Tpc44hSXO|YYm= MVixNI1O MkXINog> MV\zeZBxemW|c3XzJGxEOyCLSTDlfJBz\XO|aYPvci=> NWjkXGRkOjN6NkS3N|g>
HepG2 MUHGeY5kfGmxbjDBd5NigQ>? MWOxNI1O MkfuNlRp MY\pcohq[mm2czDzbXRKT0GULTDhcoQhUEKVUz3pcoR2[2WmIHH1eI9xcGGpeR?= MUKyN|gyPzB2MB?=
SH-SY5Y MXPGeY5kfGmxbjDBd5NigQ>? Mn3HNY1O M{HVOlI1cA>? MYnpcohq[mm2czD0bIUh[XW2b4DoZYd6KGmwZIXj[YQh[nliVF;DVC=> M4HKd|I{PzR|MUS4
SH-SY5Y NFXubmdCeG:ydH;zbZMhSXO|YYm= NF:3TlQ2dU1? NXLQd2duOWh? MXXhZo9tcXOqZYOgZ4Vt[XO2cn;sJI5mfXKxcILveIVkfGm4ZTDl[oZm[3R? MVGyN|YyQTN7NR?=
PC12  MXvGeY5kfGmxbjDBd5NigQ>? MlPyNVBuVQ>? MkfPNlRp NVT4Ro0{f2G2ZYK= MVJCpIlvcGmkaYTzJINpgW2xdIL5dJNqdi2uaXvlJJBzd3SnYYPvcYFtKGGldHn2bZR6Ng>? MlzhNlM3ODN7N{m=
OV2008 NXu3TYNCSXCxcITvd4l{KEG|c3H5 MljjOY1O M4Dq[FI1cA>? NWnCdoRm[2:wdnXyeJMhTlS\N{KwJJdqfGhiQ1TEVEBqdnSxIHHuJIFl\Gm2aY\lJIVn\mWldDD0c5diemS|IHvpcIxqdmdib4\hdolidiClYX7j[ZIh[2WubIO= NIfmOFAzOzV7MkK4NS=>
A2780 MUTBdI9xfG:|aYOgRZN{[Xl? Ml24OY1O M3vufFI1cA>? NI[1S5Rkd264ZYL0d{BHXFl5MkCge4l1cCCFRFTQJIlvfG9iYX6gZYRlcXSrdnWg[YZn\WO2IITve4Fz\HNia3nscIlv\yCxdnHybYFvKGOjbnPldkBk\Wyucx?= MXqyN|U6OjJ6MR?=
Saos-2  M3rwdWFxd3C2b4Ppd{BCe3OjeR?= Ml3sNY1O NIj5V4o6Pmh? NV7Jb3lRcW6lcnXhd4V{KGOnbHyg[IVifGhiaX7keYNm\CCkeTDQR3g> MXGyN|U3OzF5MR?=
1321N1 NUHQOndvS3m2b4TvfIlkcXS7IFHzd4F6 MmX4OY1O NWX3dmk{OjSq M4e4U5Bzd3SnY4TzJINmdGxiYXfhbY5{fCCSQ16tbY5lfWOnZDD0c5hq[2m2eR?= NV;ERZd2OjN3MkWyOlU>
SH-SY5Y MVzDfZRwfG:6aXPpeJkhSXO|YYm= NGrTXZo2dU1? Mn7RNlRp NHjxbIpqdmO{ZXHz[ZMhWEOQIITvfIlkcXS7 NF\leo4zOzV{NUK2OS=>
HT-29  MULGeY5kfGmxbjDBd5NigQ>? NF36VY4ydU1? MmD4OFgwQT[q MWPpcohq[mm2czDBUXBMKGmwZIXj[ZMh[XW2b4DoZYdq[yClZXzsJIRm[XSq NFvBXG8zOzVyOEK3Ni=>
OR6 NEDkdWJHfW6ldHnvckBCe3OjeR?= NWLITFQ{OTCvTR?= NUfiXWlTPzKq NHvyNI5{fXCycnXzd4V{KEiFVjDy[ZBtcWOjdHnvckBidmRiZn;ycYF1cW:wIH;mJIF2fG:yaHHnc5NwdWW| NHnacVUzOzN7NUi3OS=>
Hela  NHfTNIJHfW6ldHnvckBCe3OjeR?= NFHxTZM2dU1? NUjyWIROOjSq NHXM[lhqdmirYnn0d{B{fGG{dnH0bY9vNWmwZIXj[YQh[XW2b4DoZYd6 NEDTPWkzOzN7NU[3PS=>
MCF-7  NV2yfoN4TnWwY4Tpc44hSXO|YYm= NHfDRnA2dU1? MoLZNlRp NHrrV|FqdmirYnn0d{B{fGG{dnH0bY9vNWmwZIXj[YQh[XW2b4DoZYd6 M3LY[lI{Ozl3Nke5
HUVECs NUT2RVRDTnWwY4Tpc44hSXO|YYm= M1PkTlNuVQ>? NH\nToczPGh? MUficI9kc3NidHjlJJBzd3SnY4TpeoUh\W[oZXP0JI9nKHKnc4\ldoF1em:uIHL5JIlvcGmkaYTpcoch[XW2b4DoZYd6 M{PUV|I{OzV6OUK4
T24 NIrUclRHfW6ldHnvckBCe3OjeR?= MlXYNVBuVQ>? NEDSVI8ycA>? M{G3NZJm\HWlZYOgeIhmKGOuZXH2ZYdmKG:oIFzDN{Bi\nSncjDiZYlk[WyrbjD0doVifG2nboS= M{DSTFI{OzV2MEiw
U251MG  NV3VeZo6TnWwY4Tpc44hSXO|YYm= Mn33N41O NELZd|gycA>? NILPPHV{fXCycnXzd4V{KEyFMz3JTUBxem:2ZXnuJIV5eHKnc4Ppc44> Ml\INlM{Ozh4MUi=
GTL-16  MYTBdI9xfG:|aYOgRZN{[Xl? MUe1cW0> MlTGNlRp M2qzWJJm\HWlZYOgZ4VtdCC4aXHibYxqfHliYYOgZ49ueGG{ZXSgeI8h[2WubIOgeJJm[XSnZDD3bZRpKE2HVDDpcohq[mm2b4Lz NFToWoEzOzNzM{S5NC=>
T-47D NHXoNpRHfW6ldHnvckBCe3OjeR?= Ml7ZNVBuVQ>? Ml7FNog> M{TiXolvcGmkaYTzJIF2fG:yaHHnfUBxem:lZYPzJIFv\CCrbnPy[YF{\XNicnHwZY16[2mwIHnu[JVk\WRiYYDvdJRwe2m| NV\PfW42OjN|MECwNlY>
PaCa44 M1S4eWFxd3C2b4Ppd{BCe3OjeR?= MmOxNk42dU1? MkHBNYg> MVLy[YR2[2W|wrDn[Y5qeGmwLX3l[IlifGWmIHHwc5B1d3Orcx?= MUGyN|EzPDFzMh?=
MDA-MB231 NY\x[3dPTnWwY4Tpc44hSXO|YYm= NYTDPIlsPW2P MXexbC=> NUn1OIdGcW6lcnXhd4V{KHKnc4\ldoF1em:uLX3l[IlifGWmIHPhd5Bie2ViYXP0bZZifGmxbjDhcoQh[2WubDDk[YF1cA>? M4S2[FI{ODh6OEWw
HeLa NYP0[HpUSXCxcITvd4l{KEG|c3H5 NVPIWlBKOTCvTR?= MWKybC=> Mk\V[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHPvMZRz\WG2bXXueEB4cXSqIGDFTS=> MkXUNlMxODBzM{W=
SK-HEP-1 Mn;LRZBweHSxc3nzJGF{e2G7 M4\5TFExdU1? M176V|Fp MVPwdo91\WO2czDh[4FqdnO2IHH1eI9xcGGpeTDhcoQhcW6mdXPld{BieG:ydH;zbZMhcW5iYoXmZYxqdi22cnXheIVlKGOnbHzz NYHrbVhpOjJ6NUi2OFk>
HepG2 M4rhbWFxd3C2b4Ppd{BCe3OjeR?= MXuzcW0> MYK1bC=> MmDQdoVlfWOnczDj[YxtKGGyb4D0c5NqeyCrbnT1Z4VlKGK7IGHEdy=> M{X5bVIzQDN4NUm1
MCF-7  MX3GeY5kfGmxbjDBd5NigQ>? NWrxWngyOm2P NXjJOW0yOjSq NXHTcplGcW6qaXLpeJMh[XW2b4DoZYd6KGmwZIXj[YQh[nliVF5CpC=> M{H1cFI1QTdyNke2
MDA-MB-231 MX;GeY5kfGmxbjDBd5NigQ>? MU[ycW0> NInrZ3YzPGh? MYTpcohq[mm2czDheZRweGijZ4mgbY5lfWOnZDDifUBVVcLi NU\GW41DOjR7N{C2O|Y>
MCF-7  Mki4SpVv[3Srb36gRZN{[Xl? MlHnNo1O M2DVeVQ5cA>? NGTzdpFxem:vb4Tld{BVVS2rbnT1Z4VlKGOnbHyg[IVifGh? MX:yOFk4ODZ5Nh?=
MDA-MB-231 NWLrZ|lrTnWwY4Tpc44hSXO|YYm= NVzSNnFXOm2P MnuzOFhp NEC1eIlxem:vb4Tld{BVVS2rbnT1Z4VlKGOnbHyg[IVifGh? NUPhTXpzOjR7N{C2O|Y>
PANC-1  NEntR|hCeG:ydH;zbZMhSXO|YYm= M{S3ZlFuVQ>? NXHnOG0xPDiq NXPyT5h1TE2VTx?= MUPlcohidmOnczDic5J1\XqxbXniMYlv\HWlZXSgZ4VtdCC4aXHibYxqfHlibH;zdy=> MX6yOFg1OjF3OB?=
MDA-MB 231 MXLBdI9xfG:|aYOgRZN{[Xl? NVjDZmszPW2P NVG2NHJZOC53aB?= MWXtc4R2dGG2ZYOgWI9kd22rbtMuxsBqdmS3Y3XkJIFxd3C2b4Ppdy=> MmnPNlQ5OzB5OEG=
Microglia  NYDCR4NPSXCxcITvd4l{KEG|c3H5 MX[1cW0> NIrJeHIzPGh? NGq4NnJl\WO{ZXHz[ZMhcHmyb4jpZU1qdmS3Y3XkJINmdGxiZHXheIg> MljJNlQ5OTh4MEG=
A2780cp MXLBdI9xfG:|aYOgRZN{[Xl? NXP3[4tnOi53bV2= NV\WVYxOOWh? MlPz[IRJOk9? M{XXR4VvcGGwY3XzJINqe3CuYYTpck1qdmS3Y3XkJINmdGxiZHXheIg> MoToNlQ5OTd7NE[=
HepG2 MWTGeY5kfGmxbjDBd5NigQ>? NHPSeo82dU1? NIXVcJA1cA>? NE[4dFhqdmO{ZXHz[ZMh[2WubIXsZZIhdGW4ZXzzJI9nKEiOwrC= M2jsXFI1PzF|NUi3
U2OS NIfsSXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUGy[o5[OTCvTR?= MlrvNlRp MWHpcpRmdnOrZnnld{B1cGViZ4Lve5RpKGmwaHnibZRqd25iaX7keYNm\CCkeTDEc5g> Mn;5NlQ3OzlyMUO=
HCT116 NV3Fe|hwSXCxcITvd4l{KEG|c3H5 MUS1cW0> MW[yOIg> NHPVO|hFVVOR M2P5fIVvcGGwY3XzJIFxcWenbnnuMYlv\HWlZXSgZ4VtdCCmZXH0bC=> NYPRZ3lVOjR4Mk[1NlI>
MCF-7  MoToRZBweHSxc3nzJGF{e2G7 NIDTPYYxNjGvTR?= Mn3kOog> M3nxd4VvcGGwY3XzJJNqenSrbn;sMYlv\HWlZXSgZZBweHSxc3nz M2nNdFIzPzVzOUi5
PC-3  MVLBdI9xfG:|aYOgRZN{[Xl? MkTZNo1O MVGybC=> MmH6bY5kemWjc3XzJG9TUS2rbnT1Z4VlKGOnbHyg[IVifGh? NGHKOFEzOjd2NUW4NC=>
U251  NH\RSI9CeG:ydH;zbZMhSXO|YYm= MlTWOY1O Ml7BNlRp MWXpcoNz\WG|ZYOgV|EucW6mdXPl[EBk\WyuIHTlZZRp NHPn[20zOjV5OUe4PC=>
HeLa  MVrBdI9xfG:|aYOgRZN{[Xl? MUS1cW0> MnPUNlRp MXXpcoR2[2W|IHPhd5Bie2VvZHXw[Y5l\W62IHPlcIwh\GWjdHi= NUfCfJBZOjJ3NEWxNlg>
A549 NHn4bY5HfW6ldHnvckBCe3OjeR?= MlzFNE4ydU1? M3Tx[FI1cA>? Mkfod5VxeHKnc4Pld{BUXTFzMke0MYlv\HWlZXSgZ4VtdCCmZXH0bC=> Mn7RNlI1PjZ7NkC=
pDCs NFLWXJVHfW6ldHnvckBCe3OjeR?= MnS2NVBuVQ>? MYewMlVp MkjyxsBz\WS3Y3XzJJRp\SCrbnT1Z5Rqd25ib3[gTWZPNc7zIHL5JJN{Wk6DNEC= NHnyT5gzOjN7NkW5PS=>
BGC-823 M1XoS2Z2dmO2aX;uJGF{e2G7 MkS4OY1O MVmybC=> MXrpcohq[mm2czD0bIUhemG2ZTDv[kBifXSxcHjh[4lkKGOnbHzz M2PRb|IzOzJ{MUWy
U937 NYLqdmhzTnWwY4Tpc44hSXO|YYm= MYWycW0> MV2xNog> NHvYNVVl\WO{ZXHz[ZMhfGinIHH1eI9xcGGpeTDyZZRqd8Li NUWyd5RtOjJzNUWxOVA>
Marc-145 M2GyZ2Z2dmO2aX;uJGF{e2G7 MV61cW0> Mn;ONVIwOjRxM{\o NXrUdmcxemWmdXPld{B1cGViUGLSV3YhfGm2ZYLzJIFv\CC2aHWgdJJwfGWrbjDlfJBz\XO|aX;u M{L2SVIzOTF7OUCw
HBx  NUToSVVSSXCxcITvd4l{KEG|c3H5 NX3VeZVyOTCvTR?= MVi0PIg> M37qO2ROW09? NHe2cZFqdmO{ZXHz[ZMh[2WubDDk[YF1cA>? NWHSVGp1OjJyMkCwO|g>
MCF-7 NVjybGVZTnWwY4Tpc44hSXO|YYm= NGjrTYoyOG2P NYPoeFFFPDiq Mme3Zoxw[2u|IHH1eI9xcGGpeTDpcoR2[2WmIHL5JIJwenSnen;tbYI> MVSyNVk{OTl|Nx?=
RMPI8226  NUC2PFViTnWwY4Tpc44hSXO|YYm= M2PqWFVuVQ>? NHu1RXoycA>? NV[yTlVle3WycILld5NmeyC2aHWgcIV3\Wxib3[gZZV1d3CqYXf5JJVv\GW{IH71eJJq\W62IHTldIxmfGmxbh?= M4LueFIyQTF3NkKw
PC12/TetOn MWXGeY5kfGmxbjDBd5NigQ>? NWXYZXp6OC5zL{HtUS=> NXT2S5VQOTiq MmrucIVi\HNidH:g{tEue3mwKGfULUBi[2O3bYXsZZRqd25uIITvfIlkcXS7LDDhcoQhd2yrZ3;t[ZIh\m:{bXH0bY9vyqB? NUDxbItZOjF7ME[2OVk>
HeLa  NXHzNHU{S3m2b4TvfIlkcXS7IFHzd4F6 MVKycW0> MYeyOIg> MWjpcohq[mm2ZYOgeIhmKGO7dH;0c5hq[2m2eTDv[kB{cWyrYnnubY4hfG9iSHXMZUBk\Wyucz6= M2q5XFIyQDd3M{i1
Jurkat MYTGeY5kfGmxbjDBd5NigQ>? NETzbWcyOG2P NEPVUFYycA>? NIjW[|Jl\WO{ZXHz[ZMhfGinIHX4dJJme3Orb36gc4YhVEN|LVnJJIFv\CC2aHWg[o9zdWG2aX;uJI9nKGG3dH;wbIFod3OxbXXz M1yzWVIyQDZ2MEO3
K562 NWrVUVd6TnWwY4Tpc44hSXO|YYm= NXTBWG9[OTCvTR?= MmK3NYg> M4rUeIRm[3KnYYPld{B1cGViZYjwdoV{e2mxbjDv[kBNSzNvSVmgZY5lKHSqZTDmc5Ju[XSrb36gc4Yh[XW2b4DoZYdwe2:vZYO= MlywNlE5PjRyM{e=
Nara-H MmDmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYi1cW0> Mk\UOFhp NIXBU5BmdmijbnPld{B1\W2|aYLvcIlufXOvZXTpZZRm\CC|dYDwdoV{e2mxbjDv[kBP[XKjLVigZ4VtdCCycn;sbYZmemG2aX;u MnTMNlE5ODVyM{O=
HUVECs NXzVb|IzTnWwY4Tpc44hSXO|YYm= M4m0cVExdU1? NH3SUmExNjWq NGnRW25l\WO{ZXHz[ZMhfGinIFHHSU1DW0GrbnT1Z4VlKGG3dH;wbIFogSCuZY\l MlL6NlE1Pjh3OUK=
HepG2 NH23dFNCeG:ydH;zbZMhSXO|YYm= NXvZ[JdbOm2P M1zYXlFp NIPoSYJmdmijbnPld{Bz[WSrYYTpc44ucW6mdXPl[EBk\WyuIHTlZZRp MljINlE1PTN4OUG=

... Click to View More Cell Line Experimental Data

体内研究 3-Methyladenine (3-MA)可以通过对磷酸肌醇3磷酸激酶(PI3K) 的作用来阻断自吞噬, 而PI3K的活性对于自噬体形成早期膜池的成核和组装是必须的。与SAH 处理组相比3-MA并不会改变出血的程度。与SAH +对照成分组相比经过3-MA预处理后会明显加重神经病学症状。3-MA处理会减少自吞噬发生[5]。 相反地,在SAH + 3-MA组里 断裂的半胱天冬酶表达量明显上调,与此一致的是与SAH + 对照成分组相比,SAH + 3-MA组中右脑皮层里原位末端标记阳性细胞数量明显增多[5]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:[4]
+ 展开

Protein degradation assay:

HeLa cells are radiolabeled for 24 hours with 0.05 mCi/mL l-[U- 14C]valine. At the end of the labeling period, cells are rinsed three times with PBS. Cells are incubated for the designated times in either full medium or EBSS with or without the presence of 10 mM 3-Methyladenine.
细胞实验:[2]
+ 展开
  • Cell lines: HeLa 细胞系
  • Concentrations: 1-10 mM
  • Incubation Time: 3 分钟
  • Method: 用台盼蓝染色法分析细胞存活率(如HeLa细胞)。简言之, 经过3-MA处理后将贴壁的与漂浮的细胞都用PBS( pH 7.4)重悬,密度控制在每毫升1-2×106。加入等体积的0.4% 台盼蓝并彻底混匀。室温孵育3分钟后用血细胞计数器对细胞计数分析。
    (Only for Reference)
动物实验:[5]
+ 展开
  • Animal Models: 体重 300-350 g 的成年雄性Sprague–Dawley 大鼠
  • Formulation: 生理盐水配制
  • Dosages: 400 nM
  • Administration: 脑室给药
    (Only for Reference)

溶解度 (25°C)

体外 Water 10 mg/mL warmed (67.04 mM)
Ethanol 4 mg/mL (26.81 mM)
DMSO 3 mg/mL warmed (20.11 mM)

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 149.15
化学式

C6H7N5

CAS号 5142-23-4
稳定性 powder
in solvent
别名 NSC 66389

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    I'm also wondering whether it can be dissolved in water,or maybe something like culture medium,normal saline solution to form 10mM solution

  • 回答:

    As the reference (http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal. pone.0035665), 3-MA, which was found to inhibit autophagy at concentrations ranging from 1 to 10 mM was directly dissolved into the culture medium at the indicated concentrations. And we tested the solubility of S2767, and found the solubility of 3-MA in DMEM is 31 mg/mL at about 40°C.

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

相关PI3K产品

Tags: 购买3-Methyladenine (3-MA) | 3-Methyladenine (3-MA)供应商 | 采购3-Methyladenine (3-MA) | 3-Methyladenine (3-MA)价格 | 3-Methyladenine (3-MA)生产 | 订购3-Methyladenine (3-MA) | 3-Methyladenine (3-MA)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID